Last reviewed · How we verify
Oral Navelbine + Carboplatin
Oral Navelbine + Carboplatin is a Combination chemotherapy (vinca alkaloid + platinum agent) Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Non-small cell lung cancer (NSCLC), Advanced or metastatic solid tumors. Also known as: Vinorelbine, Carboplat.
Oral Navelbine (vinorelbine) inhibits microtubule assembly to arrest cancer cell division, while carboplatin causes DNA crosslinking and cell death, together providing synergistic cytotoxic activity.
Oral Navelbine (vinorelbine) inhibits microtubule assembly to arrest cancer cell division, while carboplatin causes DNA crosslinking and cell death, together providing synergistic cytotoxic activity. Used for Non-small cell lung cancer (NSCLC), Advanced or metastatic solid tumors.
At a glance
| Generic name | Oral Navelbine + Carboplatin |
|---|---|
| Also known as | Vinorelbine, Carboplat |
| Sponsor | Sun Yat-sen University |
| Drug class | Combination chemotherapy (vinca alkaloid + platinum agent) |
| Target | Tubulin (vinorelbine); DNA (carboplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Navelbine is a semi-synthetic vinca alkaloid that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest in cancer cells. Carboplatin is a platinum-based alkylating agent that forms DNA adducts and interstrand crosslinks, triggering apoptosis. The combination leverages two distinct mechanisms of cytotoxicity for enhanced anti-tumor effect.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Advanced or metastatic solid tumors
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Fatigue
Key clinical trials
- A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (PHASE3)
- A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (PHASE3)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (PHASE2)
- Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer (PHASE2)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Navelbine + Carboplatin CI brief — competitive landscape report
- Oral Navelbine + Carboplatin updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Oral Navelbine + Carboplatin
What is Oral Navelbine + Carboplatin?
How does Oral Navelbine + Carboplatin work?
What is Oral Navelbine + Carboplatin used for?
Who makes Oral Navelbine + Carboplatin?
Is Oral Navelbine + Carboplatin also known as anything else?
What drug class is Oral Navelbine + Carboplatin in?
What development phase is Oral Navelbine + Carboplatin in?
What are the side effects of Oral Navelbine + Carboplatin?
What does Oral Navelbine + Carboplatin target?
Related
- Drug class: All Combination chemotherapy (vinca alkaloid + platinum agent) drugs
- Target: All drugs targeting Tubulin (vinorelbine); DNA (carboplatin)
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer (NSCLC)
- Indication: Drugs for Advanced or metastatic solid tumors
- Also known as: Vinorelbine, Carboplat
- Compare: Oral Navelbine + Carboplatin vs similar drugs
- Pricing: Oral Navelbine + Carboplatin cost, discount & access